Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul 19, 2005	FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) - GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients - General Business	View HTML FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385) 8.9 KB
Toggle SummaryJul 26, 2005	Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy - Combination of Lexiva/r and Truvada Evaluated - General Business	View HTML Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy 15.3 KB
Toggle SummaryJul 26, 2005	Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis - Combination of Lexiva/r and Truvada Evaluated - General Business	View HTML Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis 15.3 KB
Toggle SummaryJul 27, 2005	Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was General Business	View HTML Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results 403.6 KB
Toggle SummaryAug 9, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated General Business	View HTML Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock 8.2 KB
Toggle SummarySep 9, 2005	Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated General Business	View HTML Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock 8.1 KB
Toggle SummaryOct 3, 2005	New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV HCV	View HTML New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track 12.8 KB
Toggle SummaryOct 4, 2005	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on HCV	View HTML Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis 15.8 KB
Toggle SummaryOct 26, 2005	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results - VX-950 Phase Ib Combination Study Initiated -<BR> - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved - General Business	View HTML Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results 303.4 KB
Toggle SummaryOct 31, 2005	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company General Business	View HTML Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations 7.6 KB